Merlintrader
Nov 9, 6:51 PM
$CLYM Climb Bio Reports Third Quarter 2026 Financial Results and Provides Business Updates (Nov 5)
• Climb Bio reported cash, cash equivalents and marketable securities of
$227.6 million as of September 30, 2026, which the company expects to fund operations into the second half of 2028.
• R&D expenses were
$11.0 million for the three months ended September 30, 2026, compared to
$9.1 million for the comparable 2025 period.
• G&A expenses were
$5.8 million in both periods, and other income, net was
$2.3 million compared to
$2.0 million.
Full hub (catalysts, filings & latest news):
https://www.merlintrader.com/climb-bio-clym-stock-hub/?utm_source=stocktwits&utm_medium=social&utm_campaign=st-hub-giro&utm_content=clym
Free weekly catalyst newsletter — no free trials, no logins, FREE is FREE:
https://merlintrader.beehiiv.com/subscribe?utm_source=stocktwits&utm_medium=social&utm_campaign=st-hub-giro&utm_content=clym
Not investment advice.
0 replies